Montserrat G. R.
- Country
- Spain
- Department
- Gastroenterology
Research Overview
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Efruxifermin in Non-Cirrhotic NASH/MASH with Fibrosis
- Efficacy and Safety Evaluation of GSK4532990 in Adults with Alcohol-Related Liver Disease: A Phase 2, Double-Blind, Placebo-Controlled, Dose-Finding Study
- Randomized, Double-Blind, Placebo-Controlled Trial of Zinc Acexamate in Advanced Chronic Liver Disease Patients
Data & Insights
Has run more than one trial at 90 of 184 partner sites.
Specializations
Liver Disease Management
This investigator specializes in the treatment of various chronic liver conditions, with particular emphasis on metabolic dysfunction-associated steatohepatitis (MASH) and its complications.
- Compensated Cirrhosis
- Advanced Chronic Liver Disease
- Fibrosis Management
The investigator's work encompasses therapeutic approaches for liver disease progression and fibrosis regression.
Metabolic Liver Disorders
Focused on innovative treatments for metabolic dysfunction-associated steatotic liver disease, including advanced therapeutic interventions for various stages of liver damage.
- MASH/NASH Treatment
- Liver Fibrosis Assessment
- Disease Progression Monitoring
The research extends to evaluating novel therapeutic agents for metabolic liver conditions.
Alcohol-Related Liver Disease
Specializes in the investigation of treatments for alcohol-related liver disease, focusing on innovative therapeutic approaches and disease management strategies.
- Liver Stiffness Measurement
- MELD Score Improvement
- Clinical Outcomes Assessment
The investigator evaluates novel therapeutic interventions for alcohol-induced liver complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.